Evidence map›Paper›PMID 37856197›Full record

ArticleJournal of the National Comprehensive Cancer Network : JNCCN2023

Identification and Characterization of Avoidable Hospital Admissions in Patients With Lung Cancer.

Eric M Lander, Xuanyi Li, Li-Ching Huang, Amanda S Cass, Wade T Iams, Emily A Skotte, Jennifer G Whisenant, Robert A Ramirez, Sally J York, Travis J Osterman and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the National Comprehensive Cancer Network : JNCCN, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Palliative care interventions for thoracic cancer: a systematic review and meta-analysis identifying the core elements.European respiratory review : an official journal of the European Respiratory Society · 2026
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Eric M Lander1Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Xuanyi Li1Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Li-Ching Huang2Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
Amanda S Cass3Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
Wade T Iams3Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
Emily A Skotte3Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
Jennifer G Whisenant3Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
Robert A Ramirez3Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
Sally J York3Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
Travis J Osterman3Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
Jennifer A Lewis1Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Christine M Lovly3Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
Yu Shyr3Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
Leora Horn3Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
Vanderbilt University · USVanderbilt University Medical Center · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8M
Vanderbilt Scholars in T4 Translational Research (V-STTaR) ProgramK12HL137943 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KRIPALANI, SUNIL, ROUMIE, CHRISTIANNE L. · 2017 to 2021
$2.9M
VOLT (Vanderbilt Oncology Training Program)T32CA217834 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Douglas B Johnson · 2018 to 2026
$2.7M
NCI NIH HHS P30 CA068485NCI NIH HHS T32 CA217834NHLBI NIH HHS K12 HL137943
6 · The paper itself

Abstract

backgroundMore than 50% of patients with lung cancer are admitted to the hospital while receiving treatment, which is a burden to patients and the healthcare system. This study characterizes the risk factors and outcomes of patients with lung cancer who were admitted to the hospital.

methodsA multidisciplinary oncology care team conducted a retrospective medical record review of patients with lung cancer admitted in 2018. Demographics, disease and admission characteristics, and end-of-life care utilization were recorded. Following a multidisciplinary consensus review process, admissions were determined to be either "avoidable" or "unavoidable." Generalized estimating equation logistic regression models assessed risks and outcomes associated with avoidable admissions.

resultsIn all, 319 admissions for 188 patients with a median age of 66 years (IQR, 59-74 years) were included. Cancer-related symptoms accounted for 65% of hospitalizations. Common causes of unavoidable hospitalizations were unexpected disease progression causing symptoms, chronic obstructive pulmonary disease exacerbation, and infection. Of the 47 hospitalizations identified as avoidable (15%), the median overall survival was 1.6 months compared with 9.7 months (hazard ratio, 2.07; 95% CI, 1.34-3.19; P<.001) for unavoidable hospitalizations. Significant reasons for avoidable admissions included cancer-related pain (P=.02), hypervolemia (P=.03), patient desire to initiate hospice services (P=.01), and errors in medication reconciliation or distribution (P<.001). Errors in medication management caused 26% of the avoidable hospitalizations. Of admissions in patients receiving immunotherapy (n=102) or targeted therapy (n=44), 9% were due to adverse effects of treatment. Patients receiving immunotherapy and targeted therapy were at similar risk of avoidable hospitalizations compared with patients not receiving treatment (P=.3 and P=.1, respectively).

conclusionsWe found that 15% of hospitalizations among patients with lung cancer were potentially avoidable. Uncontrolled symptoms, delayed implementation of end-of-life care, and errors in medication reconciliation were associated with avoidable inpatient admissions. Symptom management tools, palliative care integration, and medication reconciliations may mitigate hospitalization risk.

Indexed as

Lung NeoplasmsAgedHospitalizationHospitalsHumansMiddle AgedPalliative CareRetrospective StudieshospitalizationLung CancerPalliative Carepatient outcomestargeted therapy

Identifiers

PMID37856197
PMCPMC12286420
OpenAlexW4387568341

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.